Skip to content

GLP-1 calculator

GLP-1 Weight Loss Calculator

What the Wegovy, Zepbound, Mounjaro, Foundayo and Saxenda trials found, applied to your weight: the average, the spread across 100 people, and how many reached a goal like yours.

Updated

Used to show how many people in the trial got that far.

Quick answer

In their main trials, adults without diabetes lost 14.9% of their body weight on average after 68 weeks on Wegovy 2.4 mg, 18.8% after 72 weeks on Wegovy 7.2 mg, 15.0%, 19.5% and 20.9% after 72 weeks on Zepbound or Mounjaro 5, 10 and 15 mg, 7.4% to 11.1% on the Foundayo pill and 7.4% after 56 weeks on Saxenda. On placebo, people lost 2 to 4%. Results vary widely: on Wegovy 2.4 mg, 30 in 100 people lost 20% or more, while 17 in 100 lost less than 5%.

What each medicine did in its trial

Medicine and doseTrialAverage weight lostLost 10% or moreLost 20% or more
Wegovy 2.4 mgSTEP 168 weeks14.9%placebo: 2.4%66 in 10030 in 100
Wegovy 2.4 mgwith type 2 diabetesSTEP 268 weeks9.6%placebo: 3.4%44 in 10013 in 100
Wegovy HD 7.2 mgSTEP UP72 weeks18.8%placebo: 3.9%80 in 10046 in 100
Wegovy pill 25 mgOASIS 464 weeks13.6%placebo: 2.4%60 in 10028 in 100
Zepbound / Mounjaro 5 mgSURMOUNT-172 weeks15%placebo: 3.1%69 in 10030 in 100
Zepbound / Mounjaro 10 mgSURMOUNT-172 weeks19.5%placebo: 3.1%78 in 10050 in 100
Zepbound / Mounjaro 10 mgwith type 2 diabetesSURMOUNT-272 weeks12.8%placebo: 3.2%61 in 10022 in 100
Zepbound / Mounjaro 15 mgSURMOUNT-172 weeks20.9%placebo: 3.1%84 in 10057 in 100
Zepbound / Mounjaro 15 mgwith type 2 diabetesSURMOUNT-272 weeks14.7%placebo: 3.2%65 in 10031 in 100
Foundayo 5.5 mgATTAIN-172 weeks7.4%placebo: 2.1%32 in 1006 in 100
Foundayo 5.5 mgwith type 2 diabetesATTAIN-272 weeks5.1%placebo: 2.5%23 in 1003 in 100
Foundayo 9 mgATTAIN-172 weeks8.3%placebo: 2.1%40 in 1009 in 100
Foundayo 9 mgwith type 2 diabetesATTAIN-272 weeks7%placebo: 2.5%31 in 1004 in 100
Foundayo 17.2 mgATTAIN-172 weeks11.1%placebo: 2.1%55 in 10018 in 100
Foundayo 17.2 mgwith type 2 diabetesATTAIN-272 weeks9.6%placebo: 2.5%46 in 10011 in 100
Saxenda 3 mgSCALE Obesity and Prediabetes56 weeks7.4%placebo: 3%34 in 100–
Saxenda 3 mgwith type 2 diabetesSCALE Diabetes56 weeks5.4%placebo: 1.7%22 in 100–

Log your weight next to your doses

In Mingo you set a weight goal and the weekly pace you're aiming for, see your estimated goal date, and watch each weigh-in on a chart marked with every dose change.

Rated 4.7 out of 5 on the App Store · 1,579 ratings

Where the numbers come from

Every number in this calculator is copied from the clinical-studies section of the current US prescribing information for Wegovy, Zepbound, Foundayo and Saxenda. For each medicine and dose it takes three things from one trial: the average weight lost, the share of people who lost at least 5, 10, 15 and 20% (Saxenda’s label reports only 5% and more than 10%, so its chart has three groups instead of five), and the placebo group for comparison. Your weight is then multiplied by those percentages.

Two things it deliberately doesn’t do:

  • It doesn’t draw a week-by-week curve. The labels report weight at the end of each trial, not at every week, and a smooth line between “week 0” and “week 72” would look more precise than the evidence is.
  • It doesn’t mix numbers from different analyses. Trials report results in more than one way (for example, counting everyone who started, or only people who stayed on the medicine), and the second way gives bigger numbers. The labels use the first, more conservative one for every medicine here, so the doses can be compared fairly.

The average hides a wide range

An average of 15% doesn’t mean most people lose 15%. In the Wegovy 2.4 mg trial, the spread looked like this out of every 100 people (Wegovy prescribing information):

Weight lost after 68 weeks People out of 100
20% or more 30
15 to 20% 18
10 to 15% 18
5 to 10% 17
Less than 5% 17

That’s why the calculator shows 100 dots instead of one number. If your goal is to lose 20%, the useful question isn’t “what’s the average?” but “how many people got there?”, and the answer changes a lot by medicine and dose: 30 in 100 on Wegovy 2.4 mg, 46 in 100 on Wegovy 7.2 mg, and 30, 50 and 57 in 100 on Zepbound or Mounjaro 5, 10 and 15 mg.

With type 2 diabetes, expect less

People with type 2 diabetes lost less weight in their own trials, on the same doses:

Medicine and dose Without diabetes With type 2 diabetes
Wegovy 2.4 mg 14.9% (STEP 1, 68 weeks) 9.6% (STEP 2, 68 weeks)
Zepbound / Mounjaro 10 mg 19.5% (SURMOUNT-1, 72 weeks) 12.8% (SURMOUNT-2, 72 weeks)
Zepbound / Mounjaro 15 mg 20.9% (SURMOUNT-1, 72 weeks) 14.7% (SURMOUNT-2, 72 weeks)
Foundayo 17.2 mg 11.1% (ATTAIN-1, 72 weeks) 9.6% (ATTAIN-2, 72 weeks)
Saxenda 3 mg 7.4% (SCALE Obesity and Prediabetes, 56 weeks) 5.4% (SCALE Diabetes, 56 weeks)

Tick “I have type 2 diabetes” and the calculator switches to those trials. For the doses that were never tested in people with diabetes (Zepbound 5 mg, Wegovy 7.2 mg and the Wegovy pill), it shows the results without diabetes and tells you so.

How fast it happens

The trials report the end result, but two of them give a look at the first months. In STEP 4, people on semaglutide had lost 10.6% on average after a 20-week run-in that included the dose steps up to 2.4 mg (Rubino et al., JAMA 2021). In SURMOUNT-4, people on tirzepatide had lost 20.9% after 36 weeks on the highest dose they could tolerate (Aronne et al., JAMA 2024). Neither group was the same as in the main trials, so treat these as rough markers, not as points on your own curve.

The slow start is by design: every GLP-1 medicine begins at a low dose and steps up every four weeks to limit stomach side effects. The Wegovy dosage chart and Zepbound dosage chart show each step.

What happens if you stop

It matters as much as the loss itself. Three trials followed people after they stopped:

Trial What happened
STEP 1 extension (semaglutide) People had lost 17.3% by week 68. One year after stopping, they had regained 11.6 percentage points, about two thirds of the loss, for a net loss of 5.6%
STEP 4 (semaglutide) From week 20 to week 68, people who stayed on lost another 7.9%; those switched to placebo regained 6.9%
SURMOUNT-4 (tirzepatide) From week 36 to week 88, people who stayed on lost another 5.5%; those switched to placebo regained 14.0%

Sources: Wilding et al., 2022; Rubino et al., 2021; Aronne et al., 2024. The labels describe these medicines as treatment for chronic weight management: the effect lasts while you take them. Any plan to stop or lower your dose is one to make with your prescriber.

Comparing medicines

Each row in the calculator comes from a different trial, with different people, so the numbers aren’t a direct contest. There is one head-to-head trial: in SURMOUNT-5, adults without diabetes on the highest tolerated dose of tirzepatide lost 20.2% after 72 weeks, against 13.7% on semaglutide (Aronne et al., NEJM 2025). Our Zepbound vs Wegovy guide covers the other differences, from side effects to how each is taken.

Saxenda’s trial was shorter (56 weeks) than the others (68 to 72), and Foundayo is a daily pill, like the Wegovy pill. Ozempic isn’t in the calculator because it isn’t approved for weight loss, and Mounjaro appears together with Zepbound because they’re the same medicine, tirzepatide, at the same doses. In the UK and EU, Mounjaro is also authorised for weight management.

Tracking your own results

A trial average tells you what’s typical; only your own weigh-ins tell you how it’s going for you. In Mingo you set a weight goal and the weekly pace you’re aiming for, see your estimated goal date, and log every weigh-in on a chart that marks each dose change, so you and your prescriber can see what each step did.

Frequently asked questions

How much weight can I lose on Wegovy?

In the STEP 1 trial, adults without diabetes on Wegovy 2.4 mg lost 14.9% of their body weight on average after 68 weeks, against 2.4% on placebo. On the 7.2 mg dose, the average in its trial was 18.8% after 72 weeks.

How much weight can I lose on Zepbound or Mounjaro?

In SURMOUNT-1, adults without diabetes lost 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg after 72 weeks, against 3.1% on placebo. Mounjaro and Zepbound are the same medicine, tirzepatide.

How much weight can I lose on Foundayo?

In ATTAIN-1, adults without diabetes lost 7.4% on 5.5 mg, 8.3% on 9 mg and 11.1% on 17.2 mg after 72 weeks, against 2.1% on placebo. On 17.2 mg, 18 in 100 lost 20% or more.

How much weight can I lose on Saxenda?

In its main trial, adults without diabetes lost 7.4% of their weight on Saxenda 3 mg after 56 weeks, against 3.0% on placebo; 62 in 100 lost at least 5% and 34 in 100 more than 10%. The label doesn't report 15% or 20%.

How much weight do people lose in the first month?

Usually not much compared with the end result, because the first month is on the lowest starting dose. The trials report weight at the end, not week by week; in one semaglutide trial, people had lost 10.6% on average after the first 20 weeks of dose increases.

Can I lose 50 pounds on a GLP-1?

It depends on where you start. For someone weighing 250 lb, 50 lb is 20% of their weight; in the trials, 30 in 100 people on Wegovy 2.4 mg and 57 in 100 on Zepbound 15 mg lost 20% or more. Enter your weight and goal to see your own numbers.

Why do people with type 2 diabetes lose less?

The trials found smaller losses in people with type 2 diabetes: 9.6% on Wegovy 2.4 mg and 12.8% and 14.7% on tirzepatide 10 and 15 mg. The reasons aren't fully settled; your prescriber can tell you what to expect.

What happens if I stop taking it?

Most people regain weight. One year after stopping Wegovy, people in a STEP 1 extension had regained about two thirds of what they lost, and in SURMOUNT-4 people who switched to placebo regained 14% of their weight over a year.

Is this calculator a prediction for me?

No. It shows what happened to people in a trial, who also had diet and exercise counseling. Your own result depends on many things the trials can't capture, so use it to set expectations and talk to your prescriber.

Why isn't Ozempic in the calculator?

Ozempic isn't approved for weight loss, and its trials measured blood sugar in people with type 2 diabetes. It's the same medicine as Wegovy, semaglutide, at doses up to 2 mg.

Sources

Updated .

  1. Wegovy prescribing information, revised 6/2026, section 14 (DailyMed)
  2. Zepbound prescribing information, revised 8/2026, section 14 (DailyMed)
  3. Foundayo prescribing information, revised 7/2026, section 14, Table 6 (DailyMed)
  4. Saxenda prescribing information, revised 2/2026, section 14, Table 4 (DailyMed)
  5. Wharton S et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med 2025
  6. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). N Engl J Med 2015
  7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
  8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022
  9. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA 2021
  10. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022
  11. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA 2024
  12. Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025

GLP-1 calculators and dose charts